BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced its financial results for the third quarter of 2026, reporting global revenues of USD 1.9 billion, a 34 % year‑on‑year increase, anchored by core product BRUKINSA (zanubrutinib) at USD 1.4 billion — including USD 1.0 billion from the U.S. market — with GAAP net income of USD 385 million, up USD 260 million year‑on‑year, alongside a multi‑faceted collaboration with Revolution Medicines and a voluntary access agreement with the U.S. government.
Financial Highlights – Q3 2026
| Item | Result | YoY Change |
|---|---|---|
| Global Revenues | USD 1.9 billion | +34 % |
| BRUKINSA (zanubrutinib) – Global | USD 1.4 billion | +34 % |
| BRUKINSA – U.S. Market | USD 1.0 billion | +36 % |
| TEVIMBRA (tislelizumab) | USD 243 million | +28 % |
| Amgen In‑Licensed Products | USD 167 million | +26 % |
| GAAP Net Income | USD 385 million | +USD 260 million vs. prior‑year period |
| Prior‑Year GAAP Net Income Base | ≈ USD 125 million (derived) | – |
Net income growth was primarily driven by revenue growth and improved operating leverage, per the company’s announcement.
Commercial Portfolio Performance
- BRUKINSA (zanubrutinib): The core BTK inhibitor franchise delivered USD 1.4 billion in quarterly sales, up 34 % year‑on‑year, with the U.S. market alone contributing USD 1.0 billion (+36 %) — roughly 71 % of global BRUKINSA revenue for the quarter (derived from rounded figures).
- TEVIMBRA (tislelizumab): The PD‑1 antibody recorded USD 243 million, up 28 % year‑on‑year, extending its growth trajectory as the company’s second strategic pillar.
- Amgen In‑Licensed Portfolio: Products in‑licensed from Amgen generated USD 167 million, up 26 % year‑on‑year, providing a third steady growth stream.
- Profitability Inflection: GAAP net income of USD 385 million marks a USD 260 million year‑on‑year improvement, reflecting the transition from growth‑at‑scale to profitable scale.
Strategic Developments – Q3 2026
| Initiative | Detail |
|---|---|
| Revolution Medicines – Clinical Collaboration | Evaluate combination regimens of select BeOne clinical‑stage oncology candidates with four of Revolution Medicines’ clinical‑stage RAS(ON) inhibitors |
| Revolution Medicines – Regional License | BeOne granted exclusive rights to develop and commercialize the aforementioned Revolution candidates in select Asian markets |
| U.S. Government Agreement | Voluntary agreement aimed at expanding patient access to innovative oncology medicines in the United States while further strengthening the company’s U.S. manufacturing footprint |
| Global Access Partnership Renewal | Partnership with the BeOne Care Foundation and The Max Foundation — a leading global health non‑profit — extended through 2028 to expand access to BRUKINSA for adult CLL patients in low‑ and middle‑income countries |
Market Impact & Outlook
- Operating Leverage Realized: With revenue up 34 % and GAAP net income improving by USD 260 million, BeOne demonstrated that its commercial scale is now translating directly into profitability.
- U.S. Momentum: BRUKINSA’s 36 % U.S. growth to USD 1.0 billion in a single quarter underscores continued share gains in the world’s largest BTK inhibitor market.
- Next‑Generation Pipeline: The Revolution Medicines collaboration adds exposure to RAS(ON) inhibitors — a frontier target class in oncology — through both combination trials and exclusive Asian commercialization rights, extending BeOne’s regional leadership.
- Policy De‑Risking: The voluntary agreement with the U.S. government on patient access and expanded U.S. manufacturing positions the company constructively amid evolving drug‑pricing and supply‑chain policy dynamics.
- Access & Brand Equity: Extending the Max Foundation partnership through 2028 broadens BRUKINSA access for CLL patients in low‑ and middle‑income countries, reinforcing the company’s global health commitments alongside commercial growth.
- Watch Items: Sustained BRUKINSA U.S. share expansion, TEVIMBRA growth in newly approved regions, initiation of the BeOne × Revolution combination studies, and full‑year profitability guidance.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding BeOne Medicines’ revenue trajectories, profitability, the Revolution Medicines collaboration, the U.S. government agreement, and global access programs. Actual results may differ due to risks including competitive and pricing dynamics, clinical trial outcomes for combination regimens, regulatory and policy developments, manufacturing expansion execution, foreign‑exchange movements, and market adoption across regions.-Fineline Info & Tech
